President, Takeda's global oncology business unit
Appears in 1 story
Leading Mimrylo's commercial launch
Polycythemia vera has been treated with bloodletting for more than a century. On August 28, the FDA approved Mimrylo (rusfertide), the first drug mimicking hepcidin, the hormone that limits iron for red blood cell production.
Updated Sep 1
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
